If you would like to submit a blog post for consideration, please email email@example.com
A variety of non-invasive treatments are available in the treatment of superficial basal cell carcinoma. A study looked at three different methods to determine the most effective approach after one, three and five years: photodynamic therapy, topical imiquimod or topical 5-fluorouracil. Continue reading “Most Effective Treatment for Superficial Basal Cell Carcinoma”
This month’s paper from JAMA Dermatology, by Weinstock et al, is instructive. The authors did a randomised trial of five per cent fluorouracil cream applied to the face, to see if a two to four week application would reduce the number of basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) in the following year. Continue reading “Can a course of fluorouracil cream reduce a person’s risk of BCC and SCC?”
A recent study looked at the efficacy of gefitinib in patients with cutaneous squamous cell carcinoma (SCC) whose cancer was not amenable to curative therapy including surgery or radiation.
The epidermal growth factor receptor plays a key role in the carcinogenesis of SCC. However, there are limited data on the efficacy of epidermal growth factor receptor inhibitors in incurable, recurrent and/or metastatic SCC. Continue reading “Gefitinib for Incurable, Recurrent or Metastatic Squamous Cell Carcinoma”
Chemotherapy could become a thing of the past for up to two thirds of cancer patients, as the federal government considers subsidising new immunotherapy treatments.
Immunotherapy treatments Optivo and Keytruda are already subsidised by the government for the treatment of patients with melanoma, lung cancer and kidney cancer. Seeking subsidisation is a slow process that has denied treatment to patients with other cancers who cannot afford therapy. Continue reading “Immunotherapy Replacing Chemotherapy in Melanoma Treatment”
Modern therapies for cutaneous lymphomas were a topic of discussion at the European Academy of Dermatology and Venereology 2017 Congress, which was held in Geneva in September 2017. Continue reading “Cutaneous Lymphomas: New Therapies in Development”
In this month’s skin cancer update video, Associate Professor Giuseppe Argenziano discusses which adjuvant therapies are most effective in the treatment of advanced melanoma.
In stage 3 melanoma patients who have their primary tumour surgically excised, five-year recurrence rates are 70 percent in patients who receive no adjuvant therapy; 64 percent in patients who receive Interferon; 59 percent in patients who receive Ipilimumab; 38 percent in patients who receive Nivolumab; and 37 percent in patients who receive a combination of target therapies. Continue reading “Skin Cancer Update with A/Prof Giuseppe Argenziano [November]”
A ‘groundbreaking’ immunotherapy drug is helping patients overcome advanced non-melanoma skin cancer.
Cemiplimab is being used at Sir Charles Gaidner Hospital in Perth as part of an international trial. Oncologist Annette Lim, who runs the trial, says most patients have responded with encouraging results.
There were strict criteria for patients to enter the trial, but early results suggest the drug could be a game-changer for non-melanoma skin cancer sufferers. Continue reading “Groundbreaking Immunotherapy Drug Beats Skin Cancer”
One of the greatest hurdles in our fight against cancer can be our own immune system, as it often self-sabotages the body’s attempts to fight invading tumours. Researchers from the University of Bonn have recently found a way to get around this immune response, using immunotherapy to achieve a significant delay in cancer growth, which thereby allows cancer sufferers to live longer as the progression of their disease is slowed down. Continue reading “Slowing Down Cancer with Immunotherapy Breakthrough”
The breakthrough PD-L1 inhibitor Avelumab (Bavencio) has been approved by the Japanese Ministry of Health, Labor and Welfare for use in Japanese patients with metastatic Merkel cell carcinoma. It is the first curative treatment for unresectable Merkel cell carcinoma and first anti-PD-L1 agent to be approved in Asia, after receiving its first global approval in the US in March and in Europe in September.
Skin cancer doctors and dermatologists may be tempted to over-treat patients with minor skin cancers in order to make a financial profit for performing higher-cost procedures, according to a symposium focusing on controversies in dermatology.
A presentation entitled “Inconvenient Truths in Skin Cancer Care” was delivered at the 26th European Academy of Dermatology and Venereology Congress by Dr Tamar Nijsten from Erasmus Medical Center in the Netherlands. The presentation highlighted concerns that dermatologists and skin physicians and might perform unnecessary treatments on minor skin cancers such as basal cell carcinoma, or prescribe high-cost drugs offering no advantage over generic-brand counterparts, because these approaches financially benefit the physicians.